TAK-426 is under clinical development by Takeda Pharmaceutical and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect TAK-426’s likelihood of approval (LoA) and phase transition for Zika Virus Infections took place on 26 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their TAK-426 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
TAK-426 is under development for the prevention of Zika virus infections. It is administered through intramuscular route. The therapeutic candidate is an inactivated, adjuvanted, whole Zika virus vaccine with aluminum hydroxide as an adjuvant.
Takeda Pharmaceutical overview
Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China and India, Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.
Quick View TAK-426 LOA Data
|Highest Development Stage|